Kentaro Ito
Matsusaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
Tailored Synthesis of Doped Non-Layered Oxide Nanosheets Using Designed Solid-State Surfactants.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: February 03, 2026
Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 31, 2025
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.
Journal: JTO clinical and research reports
Published: June 16, 2025
Pathogen detection by multiplex PCR: A comparative study of pneumonia panel, bacterial culture, and respiratory panel in Japanese patients.
Journal: Respiratory investigation
Published: March 14, 2025
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
Journal: Therapeutic advances in medical oncology
Published: February 07, 2025
Redo mitral valve repair under repeat cardiopulmonary bypass in a dog.
Journal: Veterinary surgery : VS
Published: January 21, 2025
Suitability of Specimens from Pleural Dissemination of Non-Small Cell Lung Cancer for Genetic Testing Using Forceps and Cryobiopsy.
Journal: Respiration; international review of thoracic diseases
Published: December 10, 2024
Solid-state surfactant templating for controlled synthesis of amorphous 2D oxide/oxyhydroxide nanosheets.
Journal: Nature communications
Published: June 03, 2024
Intrinsic impacts of the expression of PD-L1 on postoperative recurrence in EGFR-mutated lung adenocarcinoma.
Journal: Frontiers in oncology
Published: April 11, 2024
Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity.
Journal: Biochemical and biophysical research communications
Published: April 10, 2024
Last Updated: 09/26/2026